
Ozempic, Zepbound must warn of rare vision loss. Claims over it are already in court
On Nov. 9, the FDA ordered every GLP-1 drug, Ozempic to Zepbound, to carry a warning of rare, sudden vision loss, citing trials, its own study and published research. Its report database shows when the concern surfaced.
KeyVex News··5 min readFact-checked against 4 public records
KeyVex News··5 min readFact-checked against 4 public recordsThe short versionTap to readTap to close
- In the FDA's trial data the condition was rare: 6.4 cases per 100,000 person-years on GLP-1 drugs, against 3.8 on a placebo or another diabetes drug, from 15 cases in all.
- Reports of it on semaglutide, Ozempic's drug, were one a year to 2023. The FDA says a July 2024 study prompted its review. Reports reached 333 in 2025 and 487 in 2026 through September.
- Such counts can't show how often a condition happens. The FDA says the reports are unverified, and that publicity about an event can affect what gets reported.
- The FDA's study of real-world data on diabetes patients found no significant increase against one other kind of diabetes drug and a 43% higher risk against another.
- The FDA's notice sets no date for the new labels. BMO analysts said they see limited risk to Lilly and Novo given how rare the condition is, BioSpace reported.
The order: The FDA said on Nov. 9 that it is requiring the makers of every GLP-1 drug to add a rare eye condition, NAION, to the warnings on their labels.FDA NAION, short for non-arteritic anterior ischemic optic neuropathy, "can result in acute, painless, decreased vision in one eye, including permanent vision loss," the agency wrote.FDA Its list has 12 drugs, among them Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro, Zepbound and Foundayo.FDA Claims over the condition are already in federal court against both companies, Lilly's latest quarterly report shows.10-Q
The evidence: The FDA's trial analysis rests on few cases. Across 126 clinical trials, it counted 6.4 cases per 100,000 person-years on the drugs, against 3.8 on a placebo or another diabetes drug.FDA A person-year is one person treated for one year. The comparison rests on 15 probable cases: 10 on GLP-1 drugs and five on placebo.FDA
Why it matters: The FDA's own report database, which KeyVex reads, shows when this concern surfaced, and the FDA says what such counts cannot show.KeyVexopenFDA From 2019 through 2023 it got one report a year of NAION in a patient taking semaglutide, the drug in Ozempic and Wegovy.KeyVexFDA It got 333 in 2025 and 487 from January through September 2026.KeyVexFDA
View the data
| Received by FDA | Reports | Note |
|---|---|---|
| 2019 | 1 | |
| 2020 | 1 | |
| 2021 | 1 | |
| 2022 | 1 | |
| 2023 | 1 | |
| 2024 H1 | 6 | |
| 2024 H2 | 54 | |
| 2025 | 333 | |
| 2026 Jan-Sep | 487 |
Source: the FDA's adverse-event reports, read through KeyVex's live connection to openFDA on Nov. 9, 2026.Data
What changed in 2024
The FDA says its review began with a study by Hathaway and colleagues, published in JAMA Ophthalmology in July 2024.FDA The agency "identified several limitations" in it but decided the risk needed a closer look.FDA
Semaglutide reports went from six in the first half of 2024 to 54 in the second.KeyVexFDA Reports naming tirzepatide, the drug in Mounjaro and Zepbound, went from four in all of 2024 to 89 in 2025.KeyVexFDA
Over the same years, reports of every kind naming semaglutide about doubled, to 21,910 in 2025 from 10,434 in 2023.KeyVex Its NAION reports went from one to 333.KeyVexFDA
The FDA warns against reading too much into such counts. Its reports have "not been scientifically or otherwise verified as to a cause and effect relationship," and "publicity about an event" can affect what gets reported, its openFDA site says.openFDA The agency also wrote that the NAION reports "were challenging to interpret" because the condition's risk factors overlap with conditions common in these patients.FDA Those risk factors may include diabetes, high blood pressure and sleep apnea.FDA
What the FDA's own study found
The FDA also studied real-world patient data through its Sentinel system. That study followed adults with type 2 diabetes who started one of three kinds of diabetes drugs from 2019 to 2024.FDA
Against SGLT-2 drugs, one of the other two kinds, GLP-1 drugs showed "no statistically significant increase" in risk.FDA Against DPP-4 drugs, the third, the risk was 43% higher.FDA Its review of animal data "did not identify a mechanism" for how the drugs could raise the risk.FDA The most rigorous published studies it reviewed "consistently reported an increased risk" in patients with type 2 diabetes who started GLP-1 drugs, compared with those starting either of the other two kinds, the FDA wrote.FDA It concluded there is "a potential increased risk of rare NAION events."FDA
What it means for patients and the companies
The FDA tells patients with sudden, painless vision loss in one eye to contact a health care professional "right away."FDA It tells doctors to consider stopping the drug in a patient who develops NAION "unless the benefits of treatment clearly outweigh the risk."FDA NBC News reported that NAION has no known treatment.NBC News
Mounjaro and Zepbound sold a combined $36.51 billion in 2025, and Novo's semaglutide drugs $36.19 billion, BioSpace reported.BioSpace BMO analysts wrote that they "see limited risk" to their coverage of Novo and Lilly "given rarity in incidence," according to BioSpace.BioSpace
Both companies deny a link between NAION and their drugs, PhillyVoice reported in September.PhillyVoice "A causal relationship between GLP-1RAs, including semaglutide, and NAION cannot be confirmed based on the totality of data," a Novo spokesperson told PhillyVoice.PhillyVoice A Lilly spokesperson told ABC News that month that the company will "continue to review data, including any data regarding ophthalmic issues."ABC7
Lilly's quarterly report, filed Oct. 29, says most US lawsuits against it and Novo alleging injuries from incretin drugs, the family GLP-1s belong to, are grouped into two federal proceedings in Pennsylvania.10-Q One covers gastrointestinal injuries; "the other relating to claims of non-arteritic anterior ischemic optic neuropathy (NAION)," the report says.10-Q The claims are the plaintiffs', and the report gives no count of cases.10-Q
The FDA's notice sets no date for the new labels.FDA
Related coverage
Sources
10 sources, 4 of them public records
Public records
- FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition (Drug Safety Communication)U.S. Food and Drug Administration · Nov. 9, 2026
- FDA adverse-event reports naming semaglutide with the reaction "optic ischaemic neuropathy", counted by receive date (openFDA query)U.S. Food and Drug Administration (openFDA) · through Sept. 30, 2026; checked Nov. 9, 2026
- FDA adverse-event reports naming tirzepatide with the reaction "optic ischaemic neuropathy", counted by receive date (openFDA query)U.S. Food and Drug Administration (openFDA) · through Sept. 30, 2026; checked Nov. 9, 2026
- Eli Lilly and Company, Form 10-Q for the quarter ended Sept. 30, 2026SEC EDGAR · Oct. 29, 2026
Rules and references
- Adverse events overview (what FDA adverse-event reports can and cannot show)openFDA, U.S. Food and Drug Administration · checked Nov. 9, 2026
Reporting
- "FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness"NBC News · Nov. 9, 2026
- "FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease"BioSpace · Nov. 9, 2026
- GLP-1 weight-loss drugs and vision loss (Novo Nordisk spokesperson statement)PhillyVoice · Sept. 23, 2026
- "What GLP-1 users should know about the potential risk of a rare type of vision loss" (Eli Lilly statement)ABC7 San Francisco / ABC News · Sept. 22, 2026
Data
- FDA drug adverse-event reports (FAERS, via openFDA)KeyVex · checked Nov. 9, 2026
How we got these numbers
- Report counts are from the FDA Adverse Event Reporting System (FAERS, which the FDA now calls AEMS), read through KeyVex's live connection to openFDA on Nov. 9, 2026. A report counts when it names the drug (semaglutide or tirzepatide, by brand, generic or reported product name, whether or not the reporter suspected that drug) and the MedDRA reaction term "optic ischaemic neuropathy", and is grouped by the date the FDA received it. Semaglutide: 1 report in each year 2019 through 2023 (received Nov. 22, 2019; Jan. 13, 2020; Jan. 19, 2021; Aug. 26, 2022; March 31, 2023), 6 from Jan. 1 to June 30, 2024, 54 from July 1 to Dec. 31, 2024, 333 in 2025, 487 from Jan. 1 to Sept. 30, 2026 (142 of them from April through June and 213 from July through September) and 885 in all through Sept. 30, 2026. No reports were dated after Sept. 30, 2026 when we checked. Tirzepatide: 1 in the first half of 2024, 3 in the second, 89 in 2025, 95 from Jan. 1 to Sept. 30, 2026, 188 in all. All reports naming semaglutide, any reaction: 10,434 in 2023, 21,910 in 2025; naming tirzepatide: 20,807 in 2023 and 62,369 in 2025. One report can describe more than one reaction and more than one drug, and the database holds duplicates. These counts are not rates: the database has no count of patients taking the drugs.
- "43% higher" is the FDA's Sentinel hazard ratio of 1.43 (95% confidence interval 1.02 to 2.01) for GLP-1 drugs against DPP-4 inhibitors; against SGLT-2 inhibitors the ratio was 1.19 (0.91 to 1.54), which the FDA called not statistically significant. The trial figures are from the FDA's analysis of 126 randomized trials with 134,253 patients and 288,879 person-years of exposure. In the FDA's Sentinel study, NAION ran at 26 to 32 cases per 100,000 person-years in each of the three drug groups, all adults with type 2 diabetes, a different group of patients from the trials. The FDA gives the general rate of NAION as 2.3 to 10.2 cases per 100,000 people a year in adults over 50.
- The header image was generated for KeyVex by an image model. It is an illustration, not a photograph of a real place or product. This is a reading of public records and news reports, not medical or investment advice.







